Esthesioneuroblastoma: The Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital Experience with Craniofacial Resection, Proton Beam Radiation, and Chemotherapy

ABSTRACT

Objectives: To determine the efficacy of craniofacial resection and proton radiation for the management of esthesioneuroblastoma (ENB). Design: A retrospective chart review was performed of all patients presenting with ENB and completely managed at the Massachusetts General Hospital (MGH) and the Massachusetts Eye and Ear Infirmary (MEEI) from 1997 to 2006. Setting: A tertiary referral center. Main Outcome Measures: Disease-free and overall survival. Participants: All patients presenting with ENB and completely managed at the MGH and the MEEI from 1997 to 2006. Results: Ten patients were identified with a median follow-up time of 52.8 months. Average age at presentation was 45 years. Nasal obstruction was the most common presenting symptom. Three patients presented with Kadish stage B disease and seven with stage C. No patient had evidence of cervical or metastatic disease at presentation. Seven patients were treated with craniofacial resections (CFR) followed by proton beam radiation with or without chemotherapy. Three patients were treated with initial chemotherapy with no response. They subsequently underwent CFR followed by proton beam radiation. The 5-year disease-free and overall survival rates were 90% and 85.7%, respectively, by Kaplan-Meier analysis. No patient suffered any severe radiation toxicity. Conclusion: ENB can be safely and effectively treated with CFR followed by proton beam irradiation. Proton irradiation may be associated with less toxicity than photon irradiation. The role of chemotherapy remains unclear.

KEYWORDS

Esthesioneuroblastoma - proton radiation - craniofacial resection

REFERENCES

• 1 Berger L, Luc R, Richard D. L'esthésioneuroépithéliome olfactif.  Bull Assoc Fr Etude Cancer. 1924;  13 410-421
• 2 Bhattacharyya N, Thornton A F, Joseph M P, Goodman M L, Amrein P C. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation: results in 9 cases.  Arch Otolaryngol Head Neck Surg. 1997;  123 34-40
• 3 Dulguerov P, Allal A S, Calcaterra T C. Esthesioneuroblastoma: a meta-analysis and review.  Lancet Oncol. 2001;  2 683-690
• 4 Levine P A, Gallagher R, Cantrell R W. Esthesioneuroblastoma: reflections of a 21-year experience.  Laryngoscope. 1999;  109 1539-1543
• 5 Nishimura H, Ogino T, Kawashima M et al.. Proton-beam therapy for olfactory neuroblastoma.  Int J Radiat Oncol Biol Phys. 2007;  68 758-762
• 6 Simon J H, Zhen W, McCulloch T M et al.. Esthesioneuroblastoma: the University of Iowa experience 1978–1998.  Laryngoscope. 2001;  111 488-493
• 7 Dias F L, Sa G M, Lima R A et al.. Patterns of failure and outcome in esthesioneuroblastoma.  Arch Otolaryngol Head Neck Surg. 2003;  129 1186-1192
• 8 Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970–1990.  Laryngoscope. 1992;  102 843-849
• 9 Foote R L, Morita A, Ebersold M J et al.. Esthesioneuroblastoma: the role of adjuvant radiation therapy.  Int J Radiat Oncol Biol Phys. 1993;  27 835-842
• 10 Irish J, Dasgupta R, Freeman J et al.. Outcome and analysis of the surgical management of esthesioneuroblastoma.  J Otolaryngol. 1997;  26 1-7
• 11 Suit H, Goldberg S, Niemierko A et al.. Proton beams to replace photon beams in radical dose treatments.  Acta Oncol. 2003;  42 800-808
• 12 Gay E, Sekhar L N, Rubinstein E et al.. Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients.  Neurosurgery. 1995;  36 887-896 discussion 896-887
• 13 Munzenrider J E, Liebsch N J. Proton therapy for tumors of the skull base.  Strahlenther Onkol. 1999;  175(suppl 2) 57-63
• 14 Pommier P, Liebsch N J, Deschler D G et al.. Proton beam radiation therapy for skull base adenoid cystic carcinoma.  Arch Otolaryngol Head Neck Surg. 2006;  132 1242-1249
• 15 Kaplan E M. Nonparametric estimation from incomplete observation.  J Am Stat Assoc. 1958;  53 457-481
• 16 Kadish S, Goodman M, Wang C C. Olfactory neuroblastoma: a clinical analysis of 17 cases.  Cancer. 1976;  37 1571-1576
• 17 Levine P A, Scher R L, Jane J A et al.. The craniofacial resection—eleven-year experience at the University of Virginia: problems and solutions.  Otolaryngol Head Neck Surg. 1989;  101 665-669
• 18 Rosenthal S J, Gall K P, Jackson M, Thornton Jr A F. A precision cranial immobilization system for conformal stereotactic fractionated radiation therapy.  Int J Radiat Oncol Biol Phys. 1995;  33 1239-1245
• 19 Urie M, Goitein M, Wagner M. Compensating for heterogeneities in proton radiation therapy.  Phys Med Biol. 1984;  29 553-566
• 20 National Cancer Institute .Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Cancer Therapy Evaluation Program Web site. Available at: http://ctep.cancer.gov/reporting/ctc.html
• 21 Goldsweig H G, Sundaresan N. Chemotherapy of recurrent esthesioneuroblastoma: case report and review of the literature.  Am J Clin Oncol. 1990;  13 139-143
• 22 McElroy Jr E A, Buckner J C, Lewis J E. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.  Neurosurgery. 1998;  42 1023-1027 discussion 1027-1028
• 23 Resto V A, Eisele D W, Forastiere A et al.. Esthesioneuroblastoma: the Johns Hopkins experience.  Head Neck. 2000;  22 550-558
• 24 Lund V J, Howard D, Wei W, Spittle M. Olfactory neuroblastoma: past, present, and future?.  Laryngoscope. 2003;  113 502-507
• 25 Polonowski J M, Brasnu D, Roux F X, Bassot V. Esthesioneuroblastoma: complete tumor response after induction chemotherapy.  Ear Nose Throat J. 1990;  69 743-746
• 26 Morita A, Ebersold M J, Olsen K D et al.. Esthesioneuroblastoma: prognosis and management.  Neurosurgery. 1993;  32 706-714 discussion 714-715
• 27 Argiris A, Dutra J, Tseke P, Haines K. Esthesioneuroblastoma: the Northwestern University experience.  Laryngoscope. 2003;  113 155-160
• 28 Constantinidis J, Steinhart H, Koch M et al.. Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975–2000.  Otolaryngol Head Neck Surg. 2004;  130 567-574
• 29 McLean J N, Nunley S R, Klass C et al.. Combined modality therapy of esthesioneuroblastoma.  Otolaryngol Head Neck Surg. 2007;  136 998-1002
• 30 Loy A H, Reibel J F, Read P W et al.. Esthesioneuroblastoma: continued follow-up of a single institution's experience.  Arch Otolaryngol Head Neck Surg. 2006;  132 134-138
• 31 Austin J R, Cebrun H, Kershisnik M M et al.. Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: treatment results at the M.D. Anderson cancer center.  Skull Base Surg. 1996;  6 1-8
• 32 Wade Jr P M, Smith R E, Johns M E. Response of esthesioneuroblastoma to chemotherapy: report of five cases and review of the literature.  Cancer. 1984;  53 1036-1041
• 33 Hwang S K, Paek S H, Kim D G et al.. Olfactory neuroblastomas: survival rate and prognostic factor.  J Neurooncol. 2002;  59 217-226